Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.83 Consensus Target Price from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $25.83.

Several brokerages recently commented on CNTA. Guggenheim increased their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. BMO Capital Markets boosted their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th.

Insiders Place Their Bets

In related news, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the completion of the transaction, the insider now owns 183,266 shares in the company, valued at approximately $2,818,631.08. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00. Following the completion of the sale, the chief executive officer now directly owns 520,661 shares in the company, valued at $9,080,327.84. This trade represents a 9.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 368,023 shares of company stock valued at $6,335,574 in the last three months. 11.59% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. Atria Investments Inc lifted its stake in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares during the last quarter. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP boosted its stake in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after buying an additional 6,785 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $16.75 on Friday. The firm has a market cap of $2.21 billion, a PE ratio of -10.95 and a beta of 1.52. The stock’s fifty day moving average price is $16.77 and its two-hundred day moving average price is $14.01. Centessa Pharmaceuticals has a one year low of $6.65 and a one year high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, research analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.